ESPED survey on newly diagnosed immune thrombocytopenia in childhood: how much treatment do we give?

IF 2.4 Q1 PEDIATRICS
Hannah von Lukowicz, Paul-Gerhardt Schlegel, Christoph Härtel, Henner Morbach, Imme Haubitz, Verena Wiegering
{"title":"ESPED survey on newly diagnosed immune thrombocytopenia in childhood: how much treatment do we give?","authors":"Hannah von Lukowicz,&nbsp;Paul-Gerhardt Schlegel,&nbsp;Christoph Härtel,&nbsp;Henner Morbach,&nbsp;Imme Haubitz,&nbsp;Verena Wiegering","doi":"10.1186/s40348-021-00121-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immune thrombocytopenia (ITP) is an autoimmune disease associated with isolated thrombocytopenia, which is caused by an imbalance between platelet production and platelet destruction. Petechial and mucous membrane hemorrhages are characteristic of ITP, but life-threatening bleeding rarely occurs. Depending on the bleeding symptoms, ITP can be treated with glucocorticoids (GC), intravenous immunoglobulins (IVIG), or in severe cases, platelet transfusions. Mild bleeding does not necessarily require therapy. Using the German Surveillance Unit for rare Pediatric Diseases (ESPED) we conducted a prospective survey on ITP patients in all German Children's Hospitals between September 2018 and August 2019. We collected data on ITP, including the clinical course, therapy implementation recommendations (according to the Association of German Scientific Medical Societies guidelines), outcome, and influence of treatment regimens depending on the treating physician´s experience with ITP patients.</p><p><strong>Results: </strong>Of the 287 recorded cases of children with ITP, 268 questionnaires were sent to the authors. Two hundred seventeen of the questionnaires fulfilled the inclusion criteria. ITP affected boys and girls similarly, and the median age of manifestation was 3.5 years. The main reasons for hospitalization were thrombocytopenia, bleeding signs, hematomas, and/or petechiae. Bleeding scores were ≤ 3 in 96% of children, which corresponded to a low-to-moderately low risk of bleeding. No life-threatening bleeding was documented. The most common therapies were IVIG (n = 59), GC (n = 33), or a combination of these (n = 17). Blood products (i.e., red blood cells, platelet concentrate, and fresh frozen plasma) were given to 13 patients. Compared to the established guidelines, 67 patients were over-treated, and 2 patients were under-treated.</p><p><strong>Conclusions: </strong>Adherence to German ITP treatment guidelines is currently limited. To improve patient safety and medical care, better medical training and dissemination of the guidelines are required in line with targeted analyses of patients with serious bleeding events to identify potential risk constellations.</p>","PeriodicalId":74215,"journal":{"name":"Molecular and cellular pediatrics","volume":"8 1","pages":"11"},"PeriodicalIF":2.4000,"publicationDate":"2021-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419130/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and cellular pediatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40348-021-00121-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Immune thrombocytopenia (ITP) is an autoimmune disease associated with isolated thrombocytopenia, which is caused by an imbalance between platelet production and platelet destruction. Petechial and mucous membrane hemorrhages are characteristic of ITP, but life-threatening bleeding rarely occurs. Depending on the bleeding symptoms, ITP can be treated with glucocorticoids (GC), intravenous immunoglobulins (IVIG), or in severe cases, platelet transfusions. Mild bleeding does not necessarily require therapy. Using the German Surveillance Unit for rare Pediatric Diseases (ESPED) we conducted a prospective survey on ITP patients in all German Children's Hospitals between September 2018 and August 2019. We collected data on ITP, including the clinical course, therapy implementation recommendations (according to the Association of German Scientific Medical Societies guidelines), outcome, and influence of treatment regimens depending on the treating physician´s experience with ITP patients.

Results: Of the 287 recorded cases of children with ITP, 268 questionnaires were sent to the authors. Two hundred seventeen of the questionnaires fulfilled the inclusion criteria. ITP affected boys and girls similarly, and the median age of manifestation was 3.5 years. The main reasons for hospitalization were thrombocytopenia, bleeding signs, hematomas, and/or petechiae. Bleeding scores were ≤ 3 in 96% of children, which corresponded to a low-to-moderately low risk of bleeding. No life-threatening bleeding was documented. The most common therapies were IVIG (n = 59), GC (n = 33), or a combination of these (n = 17). Blood products (i.e., red blood cells, platelet concentrate, and fresh frozen plasma) were given to 13 patients. Compared to the established guidelines, 67 patients were over-treated, and 2 patients were under-treated.

Conclusions: Adherence to German ITP treatment guidelines is currently limited. To improve patient safety and medical care, better medical training and dissemination of the guidelines are required in line with targeted analyses of patients with serious bleeding events to identify potential risk constellations.

儿童新诊断的免疫性血小板减少症的ESPED调查:我们给予多少治疗?
背景:免疫性血小板减少症(ITP)是一种与孤立性血小板减少症相关的自身免疫性疾病,它是由血小板产生和血小板破坏之间的不平衡引起的。点状和粘膜出血是ITP的特征,但危及生命的出血很少发生。根据出血症状,ITP可以用糖皮质激素(GC)、静脉注射免疫球蛋白(IVIG)治疗,或者在严重的情况下,输注血小板。轻度出血并不一定需要治疗。利用德国罕见儿科疾病监测单位(ESPED),我们对2018年9月至2019年8月期间所有德国儿童医院的ITP患者进行了前瞻性调查。我们收集了关于ITP的数据,包括临床过程、治疗实施建议(根据德国科学医学协会指南)、结果和治疗方案的影响,这取决于治疗医生对ITP患者的经验。结果:在记录的287例ITP患儿中,向作者发放了268份问卷。217份问卷符合纳入标准。ITP对男孩和女孩的影响相似,表现的中位年龄为3.5岁。住院的主要原因是血小板减少、出血症状、血肿和/或瘀点。96%的儿童出血评分≤3分,对应于低至中低出血风险。没有危及生命的出血记录。最常见的治疗方法是IVIG (n = 59)、GC (n = 33)或这些治疗方法的联合(n = 17)。13例患者给予血液制品(即红细胞、浓缩血小板和新鲜冷冻血浆)。与既定指南相比,67例患者治疗过度,2例患者治疗不足。结论:目前对德国ITP治疗指南的依从性有限。为了改善患者安全和医疗保健,需要更好地进行医疗培训和传播准则,同时对严重出血事件的患者进行有针对性的分析,以确定潜在的风险星座。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信